Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14937220 | 0.84 | KIF11 (0.46) | — | |
| SCHEMBL10770500 | 0.83 | MEN1 (0.38) | CPA3FOLH1GRIN1GRIN2AGRIN2D | |
| SCHEMBL14746124 | 0.80 | KIF11 (0.32) | CPA3FOLH1 | |
| SCHEMBL11856881 | 0.78 | CYP2C19 (0.39) | GRIN1GRIN2AGRIN2DGRIN2CGRIN2B | |
| SCHEMBL14937219 | 0.78 | HTT (0.39) | CYP1A2 | |
| SCHEMBL6655136 | 0.77 | TAAR1 (0.41) | KCNN4 | |
| SCHEMBL14490195 | 0.77 | CYP2C19 (0.36) | CPA3FOLH1GRIN1GRIN2AGRIN2D | |
| SCHEMBL34050 | 0.77 | FOLH1 (0.43) | FOLH1CYP2C19 | |
| SCHEMBL34051 | 0.77 | FOLH1 (0.43) | FOLH1CYP2C19 | |
| SCHEMBL8659893 | 0.76 | TRPA1 (0.37) | GRIN1GRIN2AGRIN2DGRIN2CGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | TVA (ABC), LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200206356-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-07-02 | — | — | US | disclosed |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180000959-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2018-01-04 | — | — | US | disclosed |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-11-02 | — | — | US | disclosed |
| US-9750818-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-3160518-A2 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170095569-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-04-06 | — | — | US | disclosed |
| WO-2016004048-A2 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | BLEND THERAPEUTICS, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000959-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | CPA3 48/4885FOLH1 54/4885GRIN1 2518/4885 |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | CPA3 48/4885FOLH1 54/4885GRIN1 2518/4885 |
| US-20200206356-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | CPA3 48/4885FOLH1 54/4885GRIN1 2518/4885 |
| US-20170095569-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | CPA3 48/4885FOLH1 54/4885GRIN1 2518/4885 |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | CPA3 48/4885FOLH1 54/4885GRIN1 2518/4885 |
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | CPA3 48/4885FOLH1 54/4885GRIN1 2518/4885 |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | CPA3 48/4885FOLH1 54/4885GRIN1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.